KT-110
Alcohol Use Disorder (AUD) - Severe
Key Facts
About Kinnov Therapeutics
Kinnov Therapeutics is a private, Phase 3-stage biotech company focused on developing disruptive pharmacological treatments for addiction, including alcohol, tobacco, cocaine, and opioids. Its core innovation is KT-110, a patented combination of two repurposed drugs (prazosin and cyproheptadine) in a novel galenic formulation designed for once-daily dosing. Backed by over 20 years of research, the company has secured support from European funds and key partners, with its Phase 2 results published in the prestigious journal 'Addiction'.
View full company profileAbout Kinnov Therapeutics
Kinnov Therapeutics is a private, Phase 3-stage biotech company focused on developing disruptive pharmacological treatments for addiction, including alcohol, tobacco, cocaine, and opioids. Its core innovation is KT-110, a patented combination of two repurposed drugs (prazosin and cyproheptadine) in a novel galenic formulation designed for once-daily dosing. Backed by over 20 years of research, the company has secured support from European funds and key partners, with its Phase 2 results published in the prestigious journal 'Addiction'.
View full company profile